CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
In 1987, an Israeli immunologist, Dr. Zelig Eshhar from The Weizmann Institute of Science, created the world’s first “chimeric antigen receptor” (CAR).
Chimeric antigen receptors (CARs) are genetically engineered allogeneic cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer cells. The protein constructs stimulate anti-cancer T-cells, which in turn boost a patient’s immune system.
Because CARs are engineered receptors, they do not exist in nature. Today, over one hundred companies are developing CAR-T technologies from across the globe.
CAR T-cell therapy is an approach that is being explored as an alternative to conventional treatments for several forms of cancer. To date, the U.S. FDA has approved six CAR-T cell therapies, including Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti, respectively.
M&A activity has also been robust, with Celgene snagging Juno Therapeutics for $9 billion and Gilead acquiring Kite Pharma for $11.9 billion. Ranging from small start-ups to billion dollar companies, CAR-T companies have proliferated in all healthcare markets worldwide.
https://bioinformant.com/car-t-companies-the-meteoric-rise-of-cellular-immunotherapies/amp/
ارسال به دوستان